Treatment Use of 3,4-Diaminopyridine
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01765140|
Expanded Access Status : Available
First Posted : January 10, 2013
Last Update Posted : February 6, 2018
Vern C. Juel, M.D.
Information provided by (Responsible Party):
Vern C. Juel, M.D., Duke University
No Study Results Posted on ClinicalTrials.gov for this Study
|Expanded Access Status :||Available|
|Primary Completion Date :||No date given|
|Study Completion Date :||No date given|
Publications of Results:
Sanders DB, Juel VC, Harati Y, Smith AG, Peltier AC, Marburger T, Lou JS, Pascuzzi RM, Richman DP, Xie T, Demmel V, Jacobus LR, Aleš KL, Jacobus DP; Dapper Study Team. 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia. Muscle Nerve. 2018 Apr;57(4):561-568. doi: 10.1002/mus.26052. Epub 2018 Feb 2.